UPDATE: EyePoint (EYPT) - LUGANO Missed. Nine Patients Broke the Thesis.

DURAVYU missed the primary BCVA endpoint in the full LUGANO dataset and only cleared non-inferiority after management excluded 9 of 211 patients in an ad hoc analysis.